ARUP Laboratories
VC Fund
Salt Lake City, United States
ARUP Laboratories is a research and development laboratory. Their services include lab stewardship and pharmacogenetics, laboratory outreach solutions, revenue cycle management consulting, laboratory operations solutions, quality management solutions, system laboratory alignment solutions, analytics and reporting tools, and supplemental services.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries ARUP Laboratories invests in
Stages ARUP Laboratories invests in
Countries ARUP Laboratories invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Sherrie L. Perkins
|
|||
|
John Matsen
|
|||
Investment Focus
Industry
- Health Care 4 (80%)
- Biotechnology 4 (80%)
- Health Diagnostics 2 (40%)
- SaaS 1 (20%)
- Medical 1 (20%)
Stage
- Series A 3 (60%)
- Series B 1 (20%)
- Corporate Round 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Sherrie L. Perkins
CEO
|
CEO | Total investments: 0 | Find email | |
|
John Matsen
Founder
|
Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Techcyte
|
Techcyte is a cloud-based, SaaS provider and world leader in AI-based cellular digital diagnostics. that uses deep learning image analysis to help labs and clinics become more efficient and accurate. The platform is HIPAA compliant, CE marked and supports tests across hematology, cytology, bacteriology and parasitology. Techcyte's hassolutions for human, veterinary and environmental clinics and labs. Techcyte’s Clinical Pathology AI Platform uses deep machine learning to perform automated analysis of whole slide microscopy images, revolutionizing digital diagnostics for human, animal, and environmental clinics and labs. | $21M / Corporate Round / Aug 19, 2021 | |
TellBio
|
TellBio is a provider of biotechnology service. | $5M / Series A / Mar 16, 2021 | |
PierianDx
|
PierianDx is catalyzing global adoption of genomic sequencing in healthcare by empowering physicians in the laboratory and clinic to more effectively diagnose and treat patients with cancer and other complex diseases. PierianDx’s industry-leading genomic SaaS solutions, CAP and CLIA accredited laboratory, and shared knowledgebase are used by healthsystems, cancer centers and commercial laboratories worldwide driving the most integrated approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx has rapidly become the trusted source of ‘wisdom’ in every advanced genomic report. | $27M / Series B / Oct 28, 2019 | |
IDbyDNA
|
We passionately believe that infectious disease patients should be treated with the same precision that cancer patients receive today. As our population increases, our economies become more global, and we continue over-usage of broad-spectrum antibiotics, infectious diseases are going to continue to spread and become more pernicious. Our clinicalpractices must evolve with disease to become more precise in our diagnostic and treatment tools. At IDbyDNA, our goal is to accelerate these solutions and uncover the microbial world to reduce infectious disease-associated morbidity and mortality | $9M / Series A / Sep 08, 2016 | |
|
PierianDx
|
PierianDx is catalyzing global adoption of genomic sequencing in healthcare by empowering physicians in the laboratory and clinic to more effectively diagnose and treat patients with cancer and other complex diseases. PierianDx’s industry-leading genomic SaaS solutions, CAP and CLIA accredited laboratory, and shared knowledgebase are used by healthsystems, cancer centers and commercial laboratories worldwide driving the most integrated approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx has rapidly become the trusted source of ‘wisdom’ in every advanced genomic report. | $9.3M / Series A / Jan 07, 2016 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does ARUP Laboratories invest in?
ARUP Laboratories invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact ARUP Laboratories?
Public channels for ARUP Laboratories include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ARUP Laboratories?
The team at ARUP Laboratories includes Sherrie L. Perkins (CEO) and John Matsen (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
